Background: Consensus guidelines recommend repair over replacement for the surgical treatment of active native mitral valve infective endocarditis. However, contemporary practice and long-term outcome data are limited.
Definitions and Code Validation
ICD-9-CM codes for active infective endocarditis were validated in a subset of patients' medical records. The sensitivity, specificity, and positive predictive value of ICD-9-CM codes to identify active infective endocarditis defined by the modified Duke criteria 4 were 94%, 99%, and 94%, respectively. 5 Causative micro-organisms were categorized by the use of primary and secondary diagnosis codes as follows: Staphylococcus aureus (including methicillin-resistant species), other Staphylococcus species, Streptococcus species, Gram-negative bacilli, fungus, and unknown (which included culture negative and cases where the organism was not specified).
Study End Points
The primary endpoint was all-cause mortality, and secondary endpoints were recurrent endocarditis and mitral valve reoperation. Deaths were ascertained from linked state's vital statistics death records, deceased discharge disposition at any subsequent in-hospital and emergency department and ambulatory surgery visits, and additionally from the Social Security Death Master File; recurrent infective endocarditis was defined as a diagnosis of infective endocarditis in the subsequent admissions at least 6 weeks after discharge, based on the period of antibiotics treatment recommended in the current guidelines. 6 Reoperation was identified as any subsequent mitral valve repair or replacement.
Statistical Analysis
Normally distributed continuous variables were reported as means with standard deviation and compared with the t test. Categorical variables were expressed as proportions and compared with the c 2 test. Trends in mitral valve surgery were analyzed with the Cochran-Armitage trend test. Survival curves of the primary end point of all-cause mortality were constructed with Kaplan-Meier methodology and compared with log-rank test. Cumulative incidence curves for the secondary end points of recurrence of infective endocarditis and mitral reoperation were constructed with competing risk analysis as death as a competing event and compared with the Gray test. For each endpoint, multivariable Cox regression models were fit controlling for the surgery type (repair vs replacement), baseline comorbidities (age, sex, race, history of hypertension, diabetes, congestive heart failure, chronic kidney disease, coronary artery disease, atrial fibrillation, peripheral vascular disease, chronic obstructive pulmonary disease, liver disease, cancer, cerebrovascular disease, and coagulation disorders), causative organisms, admission year, state of residency, and concomitant coronary artery bypass graft and clustering patients within hospitals. For secondary outcomes with limited number of events, models were selected based on stepwise selection and fit assessed with Akaike Information Criteria. Patient demographics (age, sex, race, state of residency), admission year, and the surgery type were retained and forced into the model. In each model, proportional hazard assumption was evaluated and if violated, the interaction term between time-to-event and the surgery type were incorporated into the model and hazard ratios were calculated at different follow-up time points. For the analysis of recurrence, patients who had mitral valve reoperation before the date of recurrence or last follow-up were not censored at the time of reoperation and remained in the analysis.
As a validation of the results of multivariable analyses, the analyses described previously were repeated for all study end points using inverse probability weighting and propensity score adjustment and cohorts created by propensity score matching ( Figure E3 ). 7, 8 Propensity scores were calculated with a multivariable hierarchical logistic regression model with repair as the outcome and with patients clustered by hospitals. Patients' demographics, baseline comorbidities, causative organisms, and admission year were included in the model as covariates. The area under the receiver operating curve for the model was 0.78. For propensity matching, 1:2 match was conducted. Each outcome was assessed by fitting Cox regression models with each outcome as a dependent variable and the surgery type as a covariate with a robust sandwich variance estimator. Marginal Cox models with a robust sandwich variance estimator were used to assess the difference in outcomes in matched cohort. The results of this sensitivity analysis confirmed the main findings and are listed in Table E5 .
A subgroup analysis of the effect of individual surgeon volume on reoperation within 1 year after repair was conducted with New York State patients (individual surgeon identifiers for California were not available). Surgeons were divided into 2 groups according to whether they performed fewer or more than 25 operations for any etiology on the mitral valve annually. We selected 25 cases as the cut-off based on previous data
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suggesting this threshold is associated with improved freedom from early reoperation after mitral repair. 9 The cumulative incidence of reoperation at 1 year was calculated and compared between these 2 groups by fitting a Cox regression model. Separate subgroup analyses of predictors of survival after repair and comparative outcomes in drug users also were conducted. All tests were 2-tailed, and an alpha level of 0.05 was considered statistically significant. All statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS

Study Population
A total of 88,031 adult patients (42,647 [48.5%] in New York State and 45,384 [51.6%] in California State) who had primary mitral valve surgery for any etiologies between 1998 and 2010 were identified. Among these, 3976 patients (4.5%) were admitted to hospital with infective endocarditis. Patients who underwent concomitant aortic or tricuspid surgery (38.9%, n ¼ 1548) or who had a history of valve surgery (7.4%, n ¼ 296), heart transplant or ventricular assist device placement (<0.4%, n < 15), or drug abuse (15.2%, n ¼ 603) were excluded, leaving 1970 patients as a study cohort. Among these patients, 367 patients (18.6%) underwent mitral valve repair and 1603 (81.4%) underwent mitral replacement. The median follow-up time was 7.1 years (range 0-12 years) in the repair group and 6.5 years (range 0-12 years) in the replacement group. The propensity-matched cohort included 798 patients: 266 in the repair group and 532 in the replacement group (median follow-up time was 7.2 years [range 0-12 years] and 6.5 years [range 0-12 years], respectively). There were no significant differences in baseline demographics or comorbidities between repair and replacement groups in the matched cohort (Table E3) .
Trends in Mitral Valve Surgery for Native Valve Endocarditis
The rate of mitral valve repair increased from 10.7% in 1998 to 19.4% in 2014 (P <.001) (Figure 1 ). Patients underwent surgery in 164 hospitals (45 hospitals in New York State and 119 hospitals in California State). Between 1998 and 2014, the total institutional volume of isolated active mitral native valve endocarditis ranged from 1 to 107 cases, with a median of 10 cases. The median mitral repair rate was 12%, ranging from 0 to 100% ( Figure E2, A) . The number of surgeons who operated on at least 1 patient with isolated active mitral native valve endocarditis in New York State was 264. The total number of operations for each surgeon ranged from 1 to 39 cases, with a median of 2 cases. Among surgeons who operated on more than 5 endocarditis cases, the median repair rate was 14.3%, ranging from 0% to 84% ( Figure E2, B) . Among patients who underwent replacement, the proportion of bioprosthetic valve use significantly increased from 23.9% in 1998 to 64.7% in 2014 (P <.001).
Patient Characteristics
Patients who underwent mitral repair were younger (mean age 54.9 AE 15.3 vs 57.4 AE 14.6 years, P ¼ .005) and had fewer comorbidities; for example, in the repair group, 46.3% had congestive heart failure compared with 57.1% in the replacement group (P < .001) ( Table 1) . Patients undergoing mitral repair also were less likely to have a virulent organism; 21.3% in the repair group had Staphylococcal endocarditis compared with more than 30% in the replacement group (P <.001) ( Table 1 ). 
Mortality
The 30-day mortality after mitral valve repair for endocarditis was 3.5% versus 8.4% for mitral valve replacement (P ¼ .001) and 90-day mortality was 6.0% for repair versus 14.7% for replacement (P < .001). Mitral repair was associated with significantly better survival at 12 years than mitral replacement (adjusted hazard ratio [HR], 0.71; 95% CI, 0.57-0.88; P ¼ .002) and was 68.8% (95% confidence interval [CI], 62.5%-74.3%) versus 53.5% (95% CI, 50.6%-56.4%) respectively ( Figure 2 ). Significant predictors of late mortality included end-stage renal disease (adjusted HR, 2.62; 95% CI, 2.04-3.37; P <.001) and causative organism. Patients with Staphylococcus endocarditis had worse survival than patients with Streptococcus endocarditis (adjusted HR, 1.54; 95% CI, 1.26-1.89; P < .001) ( Table E4 ). The results of the sensitivity analysis are included in Table E5 .
Recurrence of Infective Endocarditis
Mitral repair was associated with a significantly lower rate of recurrent endocarditis than replacement. The cumulative incidence of recurrent infective endocarditis at 12 years was 4.7% (95% CI, 2.8%-7.2%) in the repair group and 9.5% (95% CI, 8.0%-11.1%) in the replacement group (Gray test, P ¼ .02). The repair group and the replacement group had a similar risk of recurrence of endocarditis up to one year after surgery (adjusted HR at 1 year 0.70; 95% CI, 0.43-1.16; P ¼ .17). After 1 year, repair was associated with significantly lower risk of recurrence than replacement (adjusted HR at 2 years 0.47; 95% CI, 0.26-0.83; P ¼ .009) and the relative risk continued to decrease over 5 years (adjusted HR at 5 years 0.14; 95% CI, 0.03-0.62; P ¼ .01) ( Figure 3 ). (The final Cox regression model is included in Table E4 , and the result of the sensitivity analysis is included in Table E5 . The 30-day mortality of recurrent endocarditis was 15.0%. 
Mitral Reoperation and Surgeon Volume
The cumulative incidence of mitral reoperation at 12 years was 9.1% (95% CI, 6.2%-12.8%) after mitral repair and 8.6% (95% CI, 7.1%-10.4%) after mitral replacement (Gray test, P ¼ .12). Patients who underwent repair had a greater risk of reoperation than those who underwent replacement up to 1 year after surgery (adjusted HR at 1 year 1.98; 95% CI, 1.28-3.05; P ¼ .002). After 1 year, the relative risk of mitral reoperation between repair and replacement was not significant (adjusted HR at 2 years 1.41; 95% CI, 0.90-2.21 and adjusted HR at 5 years 0.51; 95% CI, 0.21-1.24) (Figure 4 ). The final Cox regression model is included in Table E4 , and the result of the sensitivity analysis is included in Table E5 . The 30-day mortality after reoperation on the mitral valve was 6.5%.
Within New York State, we identified 249 patients who underwent mitral repair for active endocarditis between 1998 and 2014: 98 patients (39.4%) were operated by surgeons whose annual total case volume for mitral valve disease of any etiology was less than 25 operations, and the remaining 151 patients (60.6%) were operated on by surgeons whose annual total mitral volume was 25 or more operations. The cumulative incidence of reoperation at 1 year was significantly greater at 9.2% (95% CI, 4.5%-16.0%) for patients operated by surgeons with an annual mitral volume of fewer than 25 cases, than it was for patients operated by surgeons with annual mitral volume of 25 or more for whom the cumulative incidence of reoperation within 1 year was 2.0% (95% CI, 0.6%-5.4%) (adjusted HR 0.18; 95% CI, 0.05-0.75, P ¼ .02).
Drug Abusers
The number of drug abusers who underwent primary isolated mitral valve surgery for active endocarditis with the same exclusion criteria as the study cohort was 313. Drug abusers were much younger (mean age 43.6 AE 11.2 vs 56.9 AE 14.8 years, P <.01) than nondrug abusers, but they had significantly worse survival at 12 years (51.3% [95% CI, 44.7%-57.4%] vs 56.2% [95% CI, 53.6%-58.8%], adjusted HR, 1.65; 95% CI, 1.39-1.96; P <.001). The commonest organism was Staphylococcus (42.2% of cases, compared with 30.0% in nondrug users). In the cohort of drug abusers, the overall repair rate was 18.2% (n ¼ 57). Twelve-year survival was 55.0% (95% CI, 36.7%-70.2%) in the repair group versus 50.7% (95% CI, 43.7%-57.3%) in the replacement group (adjusted HR, 0.58; 95% CI, 0.36-0.94; P ¼ .03). The cumulative incidence of recurrent endocarditis at 12 years was 10.7% (95% CI, 4.3%-20.5%) in the repair group versus 22.6% (95% CI, 17.3%-28.3%) in the replacement group (adjusted HR, 0.44; 95% CI, 0.20-0.94; P ¼ .04). The cumulative incidence of mitral reoperation at 12 years was 5.3% (95% CI, 1.4%-13.4%) in the repair group versus 22.8% (95% CI, 16.9%-29.2%) in the replacement group (adjusted HR, 0.31; 95% CI, 0.07-1.35; P ¼ .12).
DISCUSSION
In
Active native mitral valve endocarditis encompasses a wide spectrum of disease-from isolated single segment perforations or vegetations requiring very simple repair techniques, to extensive destruction of the valve leaflet tissue and annular support requiring complex valve reconstruction or replacement. In addition, valve repair is often made more challenging by the common finding that infective endocarditis is superimposed on pre-existing valve pathology such as leaflet prolapse. This study was not designed to differentiate between the spectrum of severity of endocarditis, and it is possible that the mortality benefit that we observed with repair over replacement reflects the greater burden of valve disease in patients who underwent replacement.
The risk of recurrent endocarditis was similar for the first year after repair compared with replacement, but by 2 years patients who had undergone replacement were twice as likely as those that had undergone repair to be diagnosed with recurrent endocarditis, and by 5 years they were 10 times more likely to experience recurrent endocarditis. From what is currently understood about the pathophysiology of early and late recurrence of endocarditis, it seems likely that incomplete treatment and nosocomial (including intraoperative contamination) was equally likely to occur in patients undergoing repair or replacement; however, late reinfection was significantly more likely to occur in patients with prosthetic valves than in patients with repaired valves. This finding may have implications for consensus guideline recommendations for antibiotic prophylaxis after valve surgery, which currently do not discriminate between patients who have undergone valve repair versus replacement. 10 Perhaps more importantly, the superior freedom from recurrent endocarditis may be the primary rationale for favoring repair over replacement where feasible.
The current state of surgery for native mitral valve endocarditis captured in this registry is one of wide variations in repair rates, and failure of repair within 1 year. The overall repair rate was low, at around 20%, and it may be possible that this was dictated by severity of valve disease encountered. However, the existence of single-center reports of repair rates of 42% to 80% which include valves with extensive destruction, [11] [12] [13] [14] [15] [16] [17] [18] taken together with the wide variation in repair rates between individual surgeons and institutions observed in our analysis, suggest that surgeon experience may have an important role to play. This hypothesis is supported by our finding that mitral valve repairs performed by higher volume surgeons for endocarditis were five times less likely to require reoperation within 1 year than mitral valve repairs performed by lower volume surgeons. This finding is not unique to infective endocarditis and, in our opinion, underlines the value of concentrating surgeon experience, particularly given the fact that these patients are rarely true surgical emergencies.
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Strength and Limitations
The main strength of our study lies in the unselected surgical population with comprehensive long-term outcome data capturing recurrent endocarditis and reoperations-complications that tend to be underestimated in single-center studies in which follow-up may be limited to patients attending the same institution. The main and important limitation of our study is our inability to adjust for the severity of endocarditis, as detailed previously, and consequently it is possible that the superior outcomes observed after repair may be explained by these confounding variables. In addition, it is well recognized that the use of an administrative rather than a clinical dataset may lead to less accurate identification of endocarditis and other patient factors: however, we validated our data against clinical records and obtained high positive predictive values for the identification of active endocarditis. The ICD-9-CM codes do not allow us to distinguish reliably between drug users who are injecting and noninjecting. Finally, the secondary outcomes of patients who moved to different states or country were not captured and may therefore have been underestimated, although we believe this would affect patients undergoing repair and replacement equally.
CONCLUSIONS
Mitral valve repair for active mitral valve endocarditis is associated with improved long-term survival and lower rates of recurrent endocarditis than mitral valve replacement. The overall repair rates of active mitral endocarditis remain very low, with wide variation in repair rates and durability observed among individual surgeons and institutions. This analysis provides data supporting consensus guidelines that mitral valve repair is preferred over replacement for the surgical treatment of active native
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Conflicts of Interest Statement
Dr Chikwe received speaker honoraria from Edwards Lifesciences. The Icahn School of Medicine at Mount Sinai receives royalty payments from Edwards Lifesciences and Medtronic for intellectual property related to Dr Adams' involvement in the development of 2 mitral valve repair rings and one tricuspid valve repair ring. Dr Adams is the National Co-Principal Investigator of the CoreValve United States Pivotal Trial, which is supported by Medtronic. All other authors have nothing to disclose with regard to commercial support. None of the sponsoring organizations had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. 
